Cargando…
Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down ste...
Autores principales: | Diana, Pietro, Mankongpaisarnrung, Charoen, Atkins, Michael B., Zeck, Jay C., Charabaty, Aline |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Gastroenterology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830540/ https://www.ncbi.nlm.nih.gov/pubmed/29516018 http://dx.doi.org/10.14309/crj.2018.17 |
Ejemplares similares
-
Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018) -
Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis
por: Kaneoka, Ayaka, et al.
Publicado: (2022) -
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
por: Bergqvist, Viktoria, et al.
Publicado: (2017) -
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
por: Rapisuwon, Suthee, et al.
Publicado: (2019) -
A case of checkpoint inhibitor-induced celiac disease
por: Alsaadi, Dana, et al.
Publicado: (2019)